Experiencing delays in receiving scripts and biologic medication? Tell us in our survey!
During 2020 and 2021, some people on biologic disease modifying anti-rheumatic drugs (bDMARDs) for arthritis and other musculoskeletal conditions have reported long delays in receiving their scripts and access to their medication.
The Consumer Advisory Committees of Arthritis Australia and Musculoskeletal Australia want to know if you have also experienced similar delays and what the impact has been for you (or your child if they are on a biologic DMARD). If broad problems are evident, Musculoskeletal Australia and Arthritis Australia will work together with other relevant groups to try to address the issues causing these delays.
If you are on a biologic DMARD for your arthritis and other musculoskeletal condition/s, we’d be very grateful if you could respond to a short, online survey. It will take no more than 5 minutes of your time.
The survey closes on Monday 14 March and the results will be made available in April 2022.
Discover more...
-
Consumer Webinar: Arthritis, COVID-19 and you – answering your questions on vaccines, boosters and medicines for kids and adults
It can be hard to keep up with the health advice on COVID-19 vaccines, boosters, fourth shots, and new treatments like antivirals that can help...
-
The 1 in 7 Australians living with arthritis need more support – Arthritis Australia launches its election platform
During the 2022 federal election, Arthritis Australia sent a copy of our election platform and campaign flag to every federal MP and senator. Hundreds of...
-
Survey report on delays in receiving scripts and biologic medication
During 2020 and 2021, some people on biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) for arthritis and other musculoskeletal conditions reported long delays...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox: